Palo Alto/Princeton/Lucerne, February 15, 2018. In addition to celebrating its 26th company anniversary this year, INOVIS further enhances its well-regarded strategic consulting services by appointing a highly driven, experienced and respected pharma industry expert to run the firm’s rapidly growing division.
INOVIS is proud to announce today that it has appointed Dr. Harshal Kubavat as its Head of Strategic Consulting Services. Harshal brings the benefit of having both client and agency experience and hence offering a high degree of understanding of brand and competitor strategies, empathy for clients’ needs and pain points, but equally importantly, new innovative and pioneering ideas to enable and optimize brand and competitor strategies. Overall, Harshal’s extensive experience with the pharma industry through academic, patient-facing and commercial activities over the past ten years provide a tremendous value to brand and competitor strategy optimization, workshops, scenario planning and development of strategic frameworks.
He joins us from Roche Pharmaceuticals where he spent four years: the first two as Global International CI Manager, working for Roche’s Global Product Strategy team covering pipeline and on-market assets; he most recently was a brand manager at Roche Products Ltd in the UK, where he was responsible for marketing activities for multiple brands, leveraging his extensive experience to drive and shape a number of market facing and internal activities, including marketing materials, tender strategies, and managing the impact of generic competition. Prior, he worked for a CI consulting agency, running projects for a wide range of pharma clients in different therapeutic areas to help guide client strategy. Harshal holds a PhD in Pharmaceutical Drug Delivery from Bath University (UK) and is a UK-registered pharmacist, gaining his Master of Pharmacy at the School of Pharmacy, University of London.
In his new role at INOVIS, Harshal is responsible for managing the firm’s Strategic Consulting Services unit, which consists mainly of brand strategy optimization, workshops, scenario planning, LCM, competitor simulations (“war gaming”) as well as competitive strategy training sessions to pharma, biotech, medical devices & digital medicine clients. He reports to Dr. Baljit Singh, Managing Director and Partner in INOVIS’ Global Pharmaceuticals and Life Sciences Division.
This appointment attests to INOVIS’ growth strategy aimed at improving competitive strategies for our clients through experienced senior industry talent who can enable further strategic thinking with impact on company and brand strategies. Furthermore, INOVIS’ unique Client Strategy and Experience Optimization (CSEO) process is aimed at maximizing each client’s collaboration and partnership experience with INOVIS – including strategic consulting - to achieve the highest possible ROI, which in turns fosters long-term, decade-long client partnerships. This latest senior team expansion exemplifies Limacher’s and Singh’s commitment to continue to be at the forefront of the CI and strategic consulting industry. “Harshal’s tested and proven track record and experience in running strategy workshops in Big Pharma environments bring implications analysis and scenarios “alive” by entertaining, engaging and ultimately actionable client team interactions and outcomes, leading to tangible bottom line results and ROI for our loyal clientele,” says Marc Limacher, INOVIS’ Founder & CEO. “We are extremely excited to have Dr Harshal Kubavat lead our strategic consulting business. He is a proven high performer and exceptionally talented. His significant scientific and commercial background, combined with his positive to-do attitude makes him a perfect fit to help drive and enable company and brand strategies” says Baljit Singh, INOVIS’ Managing Director & Partner.
Palo Alto/Princeton/Lucerne, February 13, 2017 - -
In addition to celebrating its 25th company anniversary this year, INOVIS builds out its leadership position in the CI industry with the addition of two experienced, competent, driven, and talented professionals to the company – a continued key quality differentiator which will help shape the future of the firm and the CI industry.
First, INOVIS is proud to announce today that it has appointed a senior-level executive from Mylan as its new Senior Director of Key Accounts. She has over 23 years of experience in the pharmaceutical industry. She joins us from Mylan where she most recently held the position of Global Therapeutic Area Head Women’s Health. Throughout her career, she has held a number of leadership roles in global marketing, commercial, and business intelligence at major pharmaceutical companies such as Abbott, Solvay Pharmaceuticals, and Ferring. She has extensive experience in multiple therapeutic categories and across several continents. She holds an MBA from Pfeiffer University in North Carolina, USA and a BA from Lawrence University in Wisconsin.
In her new role at INOVIS, she is responsible for key strategic client relationships among INOVIS’ pharma, biotech and medical device clients. She reports to Dr. Baljit Singh, Managing Director and Partner in INOVIS’ Global Pharmaceuticals and Life Sciences Division based in Lucerne, Switzerland.
INOVIS is equally proud to announce the appointment of Kathleen Dean as Senior Director of Strategic Client Services in INOVIS’ IT CI division. Kathleen joins INOVIS from Hewlett Packard Enterprise (HPE), where she most recently served as a world-wide product marketing manager, driving software content marketing strategy and product evangelization. Prior, she was a senior insights manager at HPE, responsible for delivering actionable customer, market, and competitive analysis for business strategy and planning. Previously, Kathleen served in various marketing and program roles in the software business at Hewlett-Packard (HP). She has more than 16 years of experience in the IT industry and holds an MS in Technical Communications from Colorado State University. Kathleen will proactively manage strategic client relationships and further optimize the continuing INOVIS tradition of exceeding client expectations. She reports to Marc Limacher, INOVIS’ Founder and CEO.
Both appointments are part of INOVIS’ future growth strategy aimed at improving competitive strategies for our clients through experienced senior industry talent who can enable further strategic thinking with impact on company and brand strategies. Furthermore, INOVIS’ unique Client Strategy and Experience Optimization (CSEO) process is aimed at maximizing each client’s collaboration and partnership experience with INOVIS to achieve the highest possible ROI, which in turns fosters long-term, decade-long client CI partnerships. The broader reorganization emphasizes Limacher’s and Singh’s commitment to continue to be at the forefront of the CI industry. “We’re excited to have professionals of Dawn’s and Kathleen’s talent and experience join our global team, allowing us to continue to set the CI industry standard for excellence & innovation,” says Marc Limacher, INOVIS’ Founder amp; CEO.
Complex factors and multiple functions affect brand & organizational performance. Dynamic environment, competition and market pressures are becoming boundary-less.
These factors can be both ‘Internal’ or ‘External’ to the organization. Multiple functions take tactical/strategic decisions during the entire product life cycle; these decisions are often taken in isolation and are not necessary aligned to strategic goal ( or the bigger picture ).
Strategic decisions need to take into account both internal and external factors for COMPREHENSIVE review. There is a need to integrate different functional insights during the various stages of a product lifecycle. The goal is to align prioritized scenarios (risk & opportunities) across different functions during the various stages of product lifecycle.
Ensure you not only plan for risk, but also for opportunities
Palo Alto/Princeton/Lucerne/New Delhi, 15 JAN 2015
The launch of the new brand marks the completion of a broad restructuring, including new offices in India, expanded best-in-class primary competitive intelligence (CI) consultancy services for branded, generic, biosimilar, medical devices and e-health/m-health markets as well as all segments of the IT industry, competitor simulation & scenario planning workshops in four languages, and new online resources.
INOVIS – building on its strong foundation of leadership and innovation over 23 years– will continue to remain on the forefront of innovation within CI, thereby ensuring that we remain the CI partner of choice for our two target industry specializations: Life Sciences (Pharma, BioTech,etc) and IT/Telco.
“Our company has evolved and grown so much over the past 23 years that a fresh identity and brand are overdue, even if we had no other reason to change our name”, says Marc Limacher, INOVIS’ founder and Managing Director. “We really appreciate the loyalty shown by both our long-term clients and our incredibly talented team of CI analysts and market investigators across five continents during this transition, and we’re looking forward to continuing to set the CI industry standard in 2015.”
(formerly Integrated Strategic Information Services )
San Francisco/Princeton/Lucerne, 12 DEC 2014 --
INOVIS announced today that it has appointed Dr. Baljit Singh, PhD., as its new managing director and partner in the Pharmaceuticals and Life Sciences Division.
A recognized expert in competitive and research intelligence in pharma/ biotechnology and generics, he is known for both his analytical insight and his results-oriented approach.
Dr. Singh brings with him nearly a decade of client- and agency-side experience, and will assume leadership of the new INOVIS offices in India as well as overseeing the day-to-day operations of the pharmaceutical division. Dr. Singh comes to the company from Novartis Pharma AG, where he most recently served as Global Director of Integrated Insights and helped to develop competitive intelligence (CI) functions and processes which are still in effect today.
In addition to leading numerous competitor simulations and strategic scenario planning workshops, Dr. Singh spearheaded Novartis’ most comprehensive generics CI tracking program, earning him the highest honors within the global commercial organization.
Previously, Dr. Singh worked as Head of Competitive Intelligence for a major regulatory intelligence firm to help pharmaceutical clients optimize their lifecycle strategies.
Dr. Singh’s appointment is part of a broader reorganization at this leading 23-year old consultancy, that will allow founder and Managing Director Marc Limacher to shift focus to the company’s equally fast growing IT CI division.
“We’re excited to have someone of Dr. Singh’s talent and experience overseeing operations for our pharma and life sciences clients,” says Limacher. “We really appreciate the patience shown by both our long-term partners and our incredibly talented analytical team during this transition, and we’re looking forward to continue to set the CI industry standard in 2015.”